tirzepatide compound vial Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity This dual Tirzepatide | GLP1 | Medical

Trial candidates are generally adults with type 2 diabetes and a BMI over 30 who have not achieved adequate glucose or weight control with standard therapies like metformin or a single GLP-1 agonist

Semaglutide : Selective GLP-1 receptor agonist that suppresses appetite, delays gastric emptying, and enhances glucose-dependent insulin secretion

Other medical reasons for pausing treatment include severe gastrointestinal adverse effects that don't improve with dose reduction or supportive measures, acute kidney injury related to dehydration from gastrointestinal side effects, severe hypoglycemia (particularly when combined with insulin or sulfonylureas), and worsening diabetic retinopathy

[DOI] [PubMed] [Google Scholar] 9.Malm-Erjefalt M, Ekblom M, Vouis J, et al

Both prescription drugs are approved by the U.S

Navigating this world of GLP-1s is, in my opinion, very nuanced